Dabrafenib and Trametinib

DRUG6 trials

Conditions

AdjuvantCancerMelanomaNeoplasiaNeoplasmThyroid CancerTumors

Phase 1

BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma

CompletedNCT02872259

Haukeland University HospitalMelanoma

Start: 2017-02-13End: 2024-05-23Updated: 2025-01-14

Phase 2

The Drug Rediscovery Protocol (DRUP Trial)

RecruitingNCT02925234

The Netherlands Cancer InstituteCancer, Neoplasia, Neoplasm +1

Start: 2016-08-31End: 2027-12-31Target: 1550Updated: 2024-01-24

Clinical Trial in RAI-Refractory Thyroid Carcinoma Evaluating BRAF & MEK Blockade for Re-differentiation Therapy

NCT04554680

National University Hospital, SingaporeThyroid Cancer

Start: 2020-12-30End: 2022-04-30Target: 5Updated: 2021-03-05

Unknown Phase

BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients

CompletedNCT03944356

EuMelaReg gGmbHMelanoma

Start: 2019-07-01End: 2024-10-08Updated: 2025-03-12

Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic Melanoma

NCT04489433

Novartis PharmaceuticalsMelanoma

Updated: 2025-12-18

Compassionate Use Program BRAF Mutation-positive Patients in the Adjuvant Treatment of Melanoma After Surgical Resection

NCT04544202

Novartis PharmaceuticalsAdjuvant, Melanoma

Updated: 2024-11-12

Cancers2026-02-18

The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the Drug Rediscovery Protocol (DRUP).

2025-01-073 citations

The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol

Clinical Cancer Research2024-07-184 citations

Maximizing Treatment Opportunities: Assessing Protocol Waivers’ Impact on Safety and Outcome in the Drug Rediscovery Protocol

Clinical Cancer Research2024-06-272 citations

Efficacy and safety of olaparib in patients with tumors harboring alterations in homologous recombination repair pathway associated genes: Results from the Drug Rediscovery Protocol.

Journal of Clinical Oncology2024-06-013 citations

The pathway alteration load as a pan-cancer determinant of outcome of targeted therapies: Results from the Drug Rediscovery Protocol (DRUP).

Journal of Clinical Oncology2024-06-01

Phase 1b study of batiraxcept in combination with durvalumab in patients with platinum-resistant ovarian cancer.

2024-04-233 citations

Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol

Clinical Cancer Research2024-04-173 citations

Clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials.

Journal of Clinical Oncology2023-06-013 citations

Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours.

2023-03-0410 citations

ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling – a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial

BMC Cancer2023-02-2223 citations

Study protocol of the GLOW study: maximising treatment options for recurrent glioblastoma patients by whole genome sequencing-based diagnostics—a prospective multicenter cohort study

BMC Medical Genomics2022-11-046 citations

Efficacy and toxicity of vemurafenib and cobimetinib in relation to plasma concentrations, after administration via feeding tube in patients with BRAF-mutated thyroid cancer: a case series and review of literature.

2022-05-226 citations

First results of the PROMPT trial: Precision oncology allocation in patients with early castration-resistant prostate cancer following routine molecular profiling.

Journal of Clinical Oncology2022-02-162 citations

Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial Carcinoma.

2022-01-2536 citations

Olaparib monotherapy in pretreated patients with <i>BRCA1/2</i> alterations: Results of a DRUP trial cohort.

Journal of Clinical Oncology2020-05-201 citations

Afatinib as a novel potential treatment option for <i>NRG1</i> fusion-positive tumors.

Journal of Global Oncology2019-10-076 citations

Update on the Drug Rediscovery Protocol: Expanded use of existing anticancer drugs in patients with a known molecular profile.

Journal of Clinical Oncology2019-05-20

Predictive and pharmacodynamic biomarkers associated with phase II, selective and orally bioavailable AXL inhibitor bemcentinib across multiple clinical trials

Annals of Oncology2018-10-017 citations

Update on the randomised phase Ib/II study of the selective small molecule AXL inhibitor bemcentinib (BGB324) in combination with either dabrafenib/trametinib or pembrolizumab in patients with metastatic melanoma

Annals of Oncology2018-10-014 citations

5 more papers not shown

Dabrafenib and Trametinib

Sponsors

Conditions

Phase 1

Phase 2

Unknown Phase

Related Papers